scholarly journals Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

CNS Drugs ◽  
2015 ◽  
Vol 29 (6) ◽  
pp. 433-441 ◽  
Author(s):  
Daphne Robakis ◽  
Stanley Fahn
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B

scholarly journals A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

2017 ◽  
Vol 158 (51) ◽  
pp. 2023-2028
Author(s):  
József Attila Szász ◽  
Viorelia Constantin ◽  
Péter Alpár Fazakas ◽  
Eszter Blényesi ◽  
Levente Gábor Grieb ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Agonists ◽  
Disease Duration ◽  
Monoamine Oxidase Inhibitors ◽  
Monoamine Oxidase B ◽  
Advanced Stages ◽  
Therapeutic Recommendations

Abstract: Introduction: Selective monoamine oxidase B inhibitors have an accurate place in therapeutical strategy of Parkinsons’s disease. In the early stages of the disease, especially in younger patients with milder symptoms, the introduction of levodopa substitution could be efficacious in delaying; in advanced stages they are mainly used to treat motor complications, as an adjunct to levodopa. Aim: The evaluation of therapeutical strategies used in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital in order to define the role of monoamine oxidase B inhibitors. Method: This retrospective study includes all records of patients with Parkinson’s disease hospitalized between 1 January 2003 and 31 December 2016. From the 2194 reports we used data focusing on the therapeutic recommendations. Regarding disease duration, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results: From the 1183 patients in first group, 243 received monoamine oxidase inhibitors: 12 as monotherapy, 52 together with dopamine agonists, in 61 cases combined with levodopa. In 118 cases monoamine oxidase inhibitors were combined with levodopa and dopamine agonists. From 582 cases whith Parkinson’s disease for more than 5 years, 195 received monoamine oxidase B inhibitors (selegiline: 10 cases, rasagiline: 185 cases). In 429 cases we did not find accurate data regarding disease duration (selegiline: 5 cases, rasagiline: 93 cases). Conclusion: The use of monoamine oxidase B inhibitors was similar to those found in literature. The treating physicians should utilise more confidently the available therapeutical combinations. Orv Hetil. 2017; 158(51): 2023–2028.

Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease

2009 ◽  
Vol 34 (8) ◽  
pp. 1427-1432 ◽  
Author(s):  
Maroof Husain ◽  
Rakesh Shukla ◽  
Madhu Dikshit ◽  
Pradeep K. Maheshwari ◽  
Devika Nag ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease ◽  
Platelet Monoamine Oxidase

scholarly journals Monoamine oxidase B inhibitors for early Parkinson's disease

2005 ◽  
Author(s):  
Kristian Turnbull ◽  
Robert Caslake ◽  
Angus Macleod ◽  
Natalie Ives ◽  
Rebecca Stowe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Early Parkinson’S Disease

Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease

2020 ◽  
pp. 1-9 ◽  
Author(s):  
Githa Elizabeth Mathew ◽  
Jong Min Oh ◽  
Kumar Mohan ◽  
Anandkumar Tengli ◽  
Bijo Mathew ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B

▼ Safinamide for Parkinson’s disease

2018 ◽  
Vol 56 (5) ◽  
pp. 54-57
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Motor Fluctuations ◽  
Daily Activities ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Idiopathic Parkinson’S Disease ◽  
Mao B ◽  
Idiopathic Parkinson's Disease

▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.

Sign in / Sign up

Export Citation Format

Share Document